ROCK inhibition as a potential therapeutic target involved in apoptosis in hemangioma

Qiu,Ming-Ke; Wang,Shu-Qing; Pan,Chang; Wang,Yang; Quan,Zhi-Wei; Liu,Ying-Bin; Ou,Jing-Min

doi:10.3892/or.2017.5515

ROCK inhibition as a potential therapeutic target involved in apoptosis in hemangioma

Authors:
- Ming-Ke Qiu
- Shu-Qing Wang
- Chang Pan
- Yang Wang
- Zhi-Wei Quan
- Ying-Bin Liu
- Jing-Min Ou
View Affiliations

Affiliations: Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, P.R. China
Published online on: March 21, 2017 https://doi.org/10.3892/or.2017.5515
Pages: 2987-2993

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gene expression was examined in hemangiomas (HA), benign, birthmark-like tumors occurring in infancy, and confirmed in HA-derived endothelial cells (HDEC), for which cell proliferation and apoptosis were also assessed. Protein and mRNA accumulation of Rho-associated protein kinase (ROCK), vascular endothelial growth factor (VEGF), Ki-67 and proliferating cell nuclear antigen was significantly higher in proliferating phase HAs than in involuting phase HAs. In contrast, p53 and caspase-3 exhibited higher levels of accumulation in involuting than proliferating HAs. Cell apoptotic indexes were low in proliferating phase HAs and increased in involuting phase HAs. HDECs were treated with the ROCK inhibitor Y-27632. Y-27632 induced p53 expression and downregulated VEGF expression, significantly inhibited cell proliferation, and induced cell apoptosis in HA cells. The inhibitor effects were confirmed in HAs from HDEC-injected nude mice. These results indicated that ROCK is involved in p53-mediated apoptosis and VEGF expression in HA cells and suggested that such inhibition may be exploited for future HA therapies.

View Figures

View References

1	Amir J, Metzker A, Krikler R and Reisner SH: Strawberry hemangioma in preterm infants. Pediatr Dermatol. 3:331–332. 1986. View Article : Google Scholar : PubMed/NCBI
2	Bryan BA, Dennstedt E, Mitchell DC, Walshe TE, Noma K, Loureiro R, Saint-Geniez M, Campaigniac JP, Liao JK and D'Amore PA: RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J. 24:3186–3195. 2010. View Article : Google Scholar : PubMed/NCBI
3	Hogeling M, Adams S and Wargon O: A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics. 128:e259–e266. 2011. View Article : Google Scholar : PubMed/NCBI
4	Sans V, de la Roque ED, Berge J, Grenier N, Boralevi F, Mazereeuw-Hautier J, Lipsker D, Dupuis E, Ezzedine K, Vergnes P, et al: Propranolol for severe infantile hemangiomas: Follow-up report. Pediatrics. 124:e423–e431. 2009. View Article : Google Scholar : PubMed/NCBI
5	Ou JM, Ye B, Qiu MK, Dai YX, Dong Q, Shen J, Dong P, Wang XF, Liu YB, Quan ZW, et al: Knockdown of Livin inhibits growth and invasion of gastric cancer cells through blockade of the MAPK pathway in vitro and in vivo. Int J Oncol. 44:276–284. 2014.PubMed/NCBI
6	Farah IO, Begum RA and Ishaque AB: Differential protection and transactivation of P53, P21, Bcl2, PCNA, cyclin G, and MDM2 genes in rat liver and the HepG2 cell line upon exposure to pifithrin. Biomed Sci Instrum. 43:116–121. 2007.PubMed/NCBI
7	Razon MJ, Kräling BM, Mulliken JB and Bischoff J: Increased apoptosis coincides with onset of involution in infantile hemangioma. Microcirculation. 5:189–195. 1998. View Article : Google Scholar : PubMed/NCBI
8	Ou JM, Yu ZY, Qiu MK, Dai YX, Dong Q, Shen J, Wang XF, Liu YB, Quan ZW and Fei ZW: Knockdown of VEGFR2 inhibits proliferation and induces apoptosis in hemangioma-derived endothelial cells. Eur J Histochem. 58:22632014. View Article : Google Scholar : PubMed/NCBI
9	Ou JM, Qui MK, Dai YX, Dong Q, Shen J, Dong P, Wang XF, Liu YB and Fei ZW: Combined blockade of AKT/mTOR pathway inhibits growth of human hemangioma via downregulation of proliferating cell nuclear antigen. Int J Immunopathol Pharmacol. 25:945–953. 2012. View Article : Google Scholar : PubMed/NCBI
10	Ou JM, Lian WS, Qiu MK, Dai YX, Dong Q, Shen J, Dong P, Wang XF, Liu YB, Quan ZW, et al: Knockdown of IGF2R suppresses proliferation and induces apoptosis in hemangioma cells in vitro and in vivo. Int J Oncol. 45:1241–1249. 2014.PubMed/NCBI
11	Fridman JS and Lowe SW: Control of apoptosis by p53. Oncogene. 22:9030–9040. 2003. View Article : Google Scholar : PubMed/NCBI
12	Murphy PJ, Galigniana MD, Morishima Y, Harrell JM, Kwok RP, Ljungman M and Pratt WB: Pifithrin-alpha inhibits p53 signaling after interaction of the tumor suppressor protein with hsp90 and its nuclear translocation. J Biol Chem. 279:30195–30201. 2004. View Article : Google Scholar : PubMed/NCBI
13	Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, et al: Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 389:990–994. 1997. View Article : Google Scholar : PubMed/NCBI
14	Takahara A, Sugiyama A, Satoh Y, Yoneyama M and Hashimoto K: Cardiovascular effects of Y-27632, a selective Rho-associated kinase inhibitor, assessed in the halothane-anesthetized canine model. Eur J Pharmacol. 460:51–57. 2003. View Article : Google Scholar : PubMed/NCBI
15	Li Z, Han S, Wang X, Han F, Zhu X, Zheng Z, Wang H, Zhou Q, Wang Y, Su L, et al: Rho kinase inhibitor Y-27632 promotes the differentiation of human bone marrow mesenchymal stem cells into keratinocyte-like cells in xeno-free conditioned medium. Stem Cell Res Ther. 6:172015. View Article : Google Scholar : PubMed/NCBI
16	Rath N and Olson MF: Rho-associated kinases in tumorigenesis: Re-considering ROCK inhibition for cancer therapy. EMBO Rep. 13:900–908. 2012. View Article : Google Scholar : PubMed/NCBI
17	Morgan-Fisher M, Wewer UM and Yoneda A: Regulation of ROCK activity in cancer. J Histochem Cytochem. 61:185–198. 2013. View Article : Google Scholar : PubMed/NCBI
18	Kordek R, Biernat W, Alwasiak J and Liberski PP: Proliferating cell nuclear antigen (PCNA) and Ki-67 immunopositivity in human astrocytic tumours. Acta Neurochir (Wien). 138:509–512; discussion 513. 1996. View Article : Google Scholar : PubMed/NCBI
19	Wang S, Li X, Parra M, Verdin E, Bassel-Duby R and Olson EN: Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7. Proc Natl Acad Sci USA. 105:7738–7743. 2008. View Article : Google Scholar : PubMed/NCBI
20	Muller PA and Vousden KH: Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer Cell. 25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
21	McIlwain DR, Berger T and Mak TW: Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol. 5:a0086562013. View Article : Google Scholar : PubMed/NCBI
22	Sun H, Breslin JW, Zhu J, Yuan SY and Wu MH: Rho and ROCK signaling in VEGF-induced microvascular endothelial hyperpermeability. Microcirculation. 13:237–247. 2006. View Article : Google Scholar : PubMed/NCBI
23	Kroll J, Epting D, Kern K, Dietz CT, Feng Y, Hammes HP, Wieland T and Augustin HG: Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven retinal neovascularization and sprouting angiogenesis. Am J Physiol Heart Circ Physiol. 296:H893–H899. 2009. View Article : Google Scholar : PubMed/NCBI
24	Yu YF, Zhang Y, Shen N, Zhang RY and Lu XQ: Effect of VEGF, P53 and telomerase on angiogenesis of gastric carcinoma tissue. Asian Pac J Trop Med. 7:293–296. 2014. View Article : Google Scholar : PubMed/NCBI
25	Takeba Y, Matsumoto N, Watanabe M, Takenoshita-Nakaya S, Ohta Y, Kumai T, Takagi M, Koizumi S, Asakura T and Otsubo T: The Rho kinase inhibitor fasudil is involved in p53-mediated apoptosis in human hepatocellular carcinoma cells. Cancer Chemother Pharmacol. 69:1545–1555. 2012. View Article : Google Scholar : PubMed/NCBI
26	Ghahremani Farhang M, Radaelli E, Haigh K, Bartunkova S, Haenebalcke L, Marine JC, Goossens S and Haigh JJ: Loss of autocrine endothelial-derived VEGF significantly reduces hemangiosarcoma development in conditional p53-deficient mice. Cell Cycle. 13:1501–1507. 2014. View Article : Google Scholar : PubMed/NCBI
27	Ghahremani Farhang M, Goossens S and Haigh JJ: The p53 family and VEGF regulation: ‘It's complicated’. Cell Cycle. 12:1331–1332. 2013. View Article : Google Scholar : PubMed/NCBI
28	Zhang L, Ji Q, Liu X, Chen X, Chen Z, Qiu Y, Sun J, Cai J, Zhu H and Li Q: Norcantharidin inhibits tumor angiogenesis via blocking VEGFR2/MEK/ERK signaling pathways. Cancer Sci. 104:604–610. 2013. View Article : Google Scholar : PubMed/NCBI
29	Murai A, Asa Abou S, Kodama A, Sakai H, Hirata A and Yanai T: Immunohistochemical analysis of the Akt/mTOR/4E-BP1 signalling pathway in canine haemangiomas and haemangiosarcomas. J Comp Pathol. 147:430–440. 2012. View Article : Google Scholar : PubMed/NCBI
30	Ji Y, Chen S, Li K, Xiao X, Xu T and Zheng S: Upregulated autocrine vascular endothelial growth factor (VEGF)/VEGF receptor-2 loop prevents apoptosis in haemangioma-derived endothelial cells. Br J Dermatol. 170:78–86. 2014. View Article : Google Scholar : PubMed/NCBI
31	Fu Y, Zhang Q, Kang C, Zhang K, Zhang J, Pu P, Wang G and Wang T: Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo. Int J Oncol. 35:583–591. 2009.PubMed/NCBI
32	Ma X and Bai Y: IGF-1 activates the P13K/AKT signaling pathway via upregulation of secretory clusterin. Mol Med Rep. 6:1433–1437. 2012.PubMed/NCBI
33	Jahn SC, Law ME, Corsino PE, Davis BJ, Harrison JK and Law BK: Signaling mechanisms that suppress the cytostatic actions of rapamycin. PLoS One. 9:e999272014. View Article : Google Scholar : PubMed/NCBI